Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q2 FY25 and H1 FY25 Earnings Presentation
17 slides from Eris Lifesciences's earnings presentation, Oct 25, 2024
Slide 1: Investor Presentation filing letter to exchanges
EY Entrepreneur of the yea,2013 FROST & SULLIVAN Best Practices-2013 ElusIness today(YES bank Excellence Awards-2013 Eris Eris Lifesciences Limited Date: 25 October 2024 To To BSE Limited National Stock Exchange Exchange of ofIndia India Limited Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal
Slide 2: Q2 FY25 and H1 FY25 Investor Presentation
Eris ERIS L1FESCIENCES LIMITED Q2 FY Q2 FY 25 25 and H1 FY and H1 FY 25 25 INVESTOR PRESENTATION INVESTOR PRESENTATION 25th Oct 25th Oct 2024 2024 1 Eris
Slide 3: Domestic Branded Formulations - Building on Q1 Trajectory
s DOMESTIC DOMESTIC BRANDED FORMULATIONS -- BUILDING BRANDED FORMULATIONS BUILDING ON ONQ1 Q1TRAJECTORY TRAJECTORY f Headline Financials Headline Financials DBF DBFBusiness Business Highlights Highlights r Op Op Revenue (INR Cr) Revenue (INR Cr) Q1 FY 25 Q1 FY 25 Q2 FY 25 Q2 FY 25 H1 H1 FY FY 25 25
Slide 4: Strong Execution - Stronger Balance Sheet and Higher Returns
• STRONG EXECUTION STRONG EXECUTION –- STRONGER STRONGERBALANCE BALANCE SHEET SHEET AND AND HIGHER HIGHER RETURNS RETURNS Return On Capital Return On Capital Employed Employed(ROCE) (ROCE) 23% ▪• ROCE ROCE– -increase increaseof of600 600 bps bps 19% (annualized)from (annualized) fromFY24 FY24to toH1
Slide 5: Strong Execution on Manufacturing Driving DBF Gross Margin Improvement
• STRONG EXECUTION STRONG EXECUTIONON ONMANUFACTURING MANUFACTURINGDRIVING DRIVINGDBF DBFGROSS GROSSMARGIN MARGINIMPROVEMENT IMPROVEMENT 1 (1)Ramp-up 0) Ramp-upof ofEris Eris AMD AMD Site Site Operations Operation 25 22 22 80% Manufacturing at •• Manufacturing at Eris Eris 20 18 18 14 60% AMD site A
Slide 6: Successful Integration Resulting in Significant Fixed Cost Synergies
• SUCCESSFUL INTEGRATION SUCCESSFUL INTEGRATION RESULTING RESULTING IN SIGNIFICANT FIXED IN SIGNIFICANT FIXED COST COST SYNERGIES SYNERGIES Significant Scale ▪• Significant Scale benefits benefits in in Diabetes Diabetes operations operations ▪• Pre-Biocon Pre-Biocon -– INR INR ~- 600 600cr cr OHA O
Slide 7: R&D Investment Yielding Results - Our First in Market Pipeline
R&D INVESTMENT R&D INVESTMENT YIELDING YIELDING RESULTS RESULTS -- OUR OUR "FIRST “FIRST IN IN MARKET" MARKET” PIPELINE PIPELINE Candidates/ Therapy Candidates/ Therapy Development Status Development Status Commercialisation Commercialisation FY 24 FY 24 launches launches 11 FDC FDC in in Cardiovasc
Slide 8: Swiss Parenterals - Strengthening the Core; Adding Growth Engines
SWISS PARENTERALS SWISS PARENTERALS –- STRENGTHENING STRENGTHENING THE THE CORE; CORE; ADDING GROWTH ENGINES ADDING GROWTH ENGINES Business Customer-facing ▪• Customer -facing team team expanded expanded –- Six Six senior-level senior-level additions additions to to the the Integration Business Busi
Slide 9: Swiss Parenterals - Q2 and H1 Financial Update
SWISS PARENTERALS SWISS PARENTERALS –- Q2 Q2 AND AND H1 H1 FINANCIAL FINANCIAL UPDATE UPDATE Financial Performance Financial of Base Performance of Base Business Business –- RoW RoW Injectable Exports Injectable Exports Revenue -- INR Revenue INR Crore Crore EBIDTA -- INR EBIDTA INR Crore Crore Annu
Slide 10: Creating Value in Indian Biologics - Vertical Integration is Key
CREATING VALUE VALUEIN IN INDIAN INDIAN BIOLOGICS BIOLOGICS –- VERTICAL VERTICAL INTEGRATION INTEGRATION IS KEY CREATING IS KEY 4 ▪■Large Indian Indian Biologics Largeopportunity -~ INR Market Biologics Market opportunity–- revenue INR 15,000+ 15,000+ cr cr p.a. revenue base p.a. with base of with a
Slide 11: Strategic Partnership with Levim Lifetech - Strengthening Our Biotech Play
• STRATEGIC PARTNERSHIP STRATEGIC PARTNERSHIP WITH WITHLEVIM LEVIMLIFETECH LIFETECH– STRENGTHENING OUR - STRENGTHENING BIOTECH OUR PLAY BIOTECH PLAY 1 Eris Eris–- Vertically VerticallyIntegrated IntegratedBiologics Biologicspresence presence Levim Levim Deal Deal Contours Contours Product Product Bu
Slide 12: Consolidated P&L Q2 FY25 - Fixed Cost Synergies Continue to Accrue
CONSOLIDATED P&L CONSOLIDATED Q2 FY25 P&L Q2 FY25 -–FIXED FIXEDCOST COSTSYNERGIES SYNERGIES CONTINUE CONTINUE TO TOACCRUE ACCRUE Consolidated Consolidated Q2 FY Q2 FY 25 25 H11 FY FY 25 25 Q2 FY Q2 FY25 Q2FY 25 Q2 FY 24 24 H1 H1FY FY2525 H1 H1 FY FY 24 24 H Q2 consolidated •• Q2 consolidated operati
Slide 13: Ahead of Schedule in Rebuilding Balance Sheet Strength
AHEAD OF AHEAD OF SCHEDULE SCHEDULE IN REBUILDING BALANCE IN REBUILDING BALANCE SHEET SHEET STRENGTH STRENGTH Balance Balance Sheet strategy shared Sheet strategy shared at at the the end end ofof FY24 FY24 –- To reduce DebttotoEBIDTA reduce Debt EBIDTA from from 3.5x 3.5x to to << 2x 2x in in 18 18
Slide 14: Reaffirming Our Business Guidance for FY25
REAFFIRMING OUR REAFFIRMING OUR BUSINESS BUSINESS GUIDANCE GUIDANCE FOR FOR FY FY 25 25 FY 25 FY 25 –- Business Business Guidance Guidance FY 25 FY 25 –- Key Key Considerations Considerations Total DBF •• Total DBF revenue INR 2,600 revenue INR cr with 2,600 cr with EBIDTA EBIDTA margin margin ▪• De
Slide 15: Shareholder Profile
SHAREHOLDER PROFILE SHAREHOLDER PROFILE i Shareholding of Shareholding of Promoters Promoters and and Top Top 15 15 Institutional Institutional Investors Investors Shareholding Pattern Shareholding Pattern 30-Sep-24 30-Sep-24 30-Jun-24 30-Jun-24 31-Mar-24 31-Mar-24 Name of Name of Shareholder Shareh
Slide 16: Safe Harbor Statement
SAFE HARBOR SAFE HARBOR STATEMENT STATEMENT This presentation This presentation contains contains forward-looking forward-looking statements statements and information that and information that involve involve risks, risks, uncertainties uncertainties and and assumptions. Forward-looking assumptions
Slide 17: Thank You
Eris ERIS LIFESCIENCES LIMITED THANK YOU THANK YOU KRUTI RAVAL KRUTI RAVAL INVESTOR INVESTOR RELATIONS RELATIONS kruti@erislifesciences.com kruti©erislifesciences.com 16 16 Eris Lifesciences
Eris Lifesciences — Q2 FY25 and H1 FY25 Earnings Presentation on 6ix